Alivus Life — Q4 FY26 earnings call

Call held 15 May 2026

Management summary

Alivus Life Sciences delivered a strong Q4 and full year FY26 performance, marked by a 6.9% revenue growth and a historic 33.6% EBITDA margin. The strategic focus on the non-GPL segment, which grew 13% and now contributes 71% of revenue, has significantly improved business quality. Despite facing geopolitical headwinds and a fire incident, the company maintained a net debt-free position and is investing substantially in capacity expansion and R&D for sustainable future growth.

Highlights

  • Full year FY26 revenue stood at INR2,552 crores, registering a 6.9% year-on-year growth.

  • Non-GPL business led momentum with 13% growth, increasing its contribution to 71% of overall business in FY26 from 59% in FY22.

  • EBITDA margin for FY26 was 33.6%, up 360 basis points year-on-year, marking the highest in the company's history.

  • The company maintained a net debt-free position and generated strong cash flows, with cash and cash equivalents at INR782 crores as of March 31, 2026.

  • Added 11 new products and 49 new customers during FY26, expanding the total customer base to about 900.

Concerns

  • A fire incident at the Dahej plant resulted in a loss of INR20 crores booked in other expenses in Q4 FY26.

  • The company faces ongoing geopolitical conflicts, uncertainties around global demand, supply chain disruptions, and elevated logistics and energy costs.

  • Experienced a price erosion of approximately 5.5% in the non-GPL, non-CDMO base business.

  • The GPL business is described as 'wavy,' and its contribution is expected to decrease as the non-GPL business grows faster.

Key financials

2 periods

Q4 FY26

  • Revenue
    ₹689 Cr
    YoY +6.1%
  • Gross Profit
    ₹418 Cr
    YoY +14%
  • Gross Margins
    60.7%
  • EBITDA
    ₹237 Cr
    YoY +13.8%
  • EBITDA Margin
    34.4%
  • PAT
    ₹163 Cr

FY26

  • Revenue
    ₹2,552 Cr
    YoY +6.9%
  • Gross Profit
    ₹1,485 Cr
    YoY +13.7%
  • Gross Margins
    58.2%
  • EBITDA
    ₹858 Cr
    YoY +19.6%
  • EBITDA Margin
    33.6%
  • PAT
    ₹565 Cr
  • R&D Expenditure
    ₹91 Cr

What they filed

Q1 FY27: revenue up 6.3%, net profit up 31.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue507 642 650 602 588 +16%673 +5%689 +6%640 +6%
EBITDA134 190 198 172 179 +34%231 +22%215 +9%212 +23%
Net profit95 137 142 122 130 +37%150 +9%163 +15%160 +31%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Non-GPL Business
    71% Contribution to Overall Business (FY26)59% Contribution to Overall Business (FY22)13% Growth (FY26)7.5% Revenue CAGR (Past 2 years)
  • CDMO Business
    18% Growth

Capital allocation

high confidence
  • Capex ₹540 Cr entirely through internal accruals
    • Carryover commitments from FY26
    • Fresh capital investments for building new capabilities at Solapur (greenfield project)
    • Strengthening R&D platform
    Looking ahead to FY27, we plan to incur a capex of about INR540 crores, which includes carryover commitments from FY26 as well as fresh capital investments. Importantly, this entire capex will be funded through internal accruals. These investments are focused on building new capabilities at Solapur, our greenfield project as well as strengthening our R&D platform.
  • Debt Net ₹0 Cr
    As a result, we have consistently generated strong cash flows strengthened our balance sheet and maintained a net debt-free position.
  • Liquidity Cash ₹782 Cr Cash and cash equivalents stood at INR782 crores as of 31st March 2026, with a 'war chest' of INR451 crores generated from operations over the last 2 years after capex and dividend.
    As of 31st March 2026, our cash and cash equivalents stood at INR782 crores, with capex for the year being INR306 crores. ... Over the last 2 years, we have generated cash from operations of about INR984 crores, of which we have invested in capex of INR472 crores, paid dividend of INR61 crores and resulted in a war chest of INR 451 crores.

Guidance & targets

Profitability

  • EBITDA margins Profitability · going forward · High confidence 30% to 32%
    However, we remain confident in the strength of our business fundamentals and our ability to sustain EBITDA margins in the range of 30% to 32% going forward.

    — Yasir Rawjee

Capacity

  • API capacity Capacity · by FY28 · High confidence 2,690 KL

    From 1,198 KL today

    The capacity we are adding today will take us from 1,198 KL in FY24 to a planned 2,690 KL by FY28, positioning the company to drive sustained growth well beyond FY28.

    — Tushar Mistry

Operations

  • Solapur Phase 1 operational status Operations · Q2 of this year · High confidence operational
    On the capex front, Solapur Phase 1 is progressing as planned and is expected to be operational in Q2 of this year.

    — Yasir Rawjee

Capacity Utilization

  • Solapur initial utilization Capacity Utilization · when Solapur starts off · High confidence 40% to 50%
    So we expect that in when Solapur starts off, we should start off with a robust 40% to 50% utilization and then probably take it up to 60%, 70% in the following year.

    — Yasir Rawjee

  • Solapur subsequent utilization Capacity Utilization · in the following year · High confidence 60% to 70%

    — Yasir Rawjee

  • Brownfield capacity utilization Capacity Utilization · 2 to 3 quarters · High confidence kick in pretty quickly
    And brownfield will kick in pretty quickly, 2 to 3 quarters.

    — Yasir Rawjee

R&D Spend

  • R&D spend as percentage of sales R&D Spend · next year or 2, then settle down · High confidence 4%
    As far as settling down, I don't think we'll cross 4%, right? We'll probably be at 4% in the next year or 2. And then it should settle down.

    — Yasir Rawjee

CDMO Business

  • New CDMO deals closure CDMO Business · second half early second half of this year · Medium confidence 2 new deals
    As far as new projects go, we hope to close 2 new deals in the second half early second half of this year.

    — Yasir Rawjee

  • CDMO 2 contracts CDMO Business · early second half of FY27 · Medium confidence come in

    Previously next 6 months (June, July) → come in

    Not really expecting delays, but then I do want to moderate it a little bit. It may come in the first half also, a little later in the first half. But just to be on the safe side, we are saying it will happen on the early part of second half.

    — Yasir Rawjee

What to watch in Q1 FY27

Solapur Phase 1 operational status

Q2 FY27
Current Progressing as planned
Target Operational

Why it matters

Commissioning of Solapur Phase 1 is key for new capabilities and future capacity expansion.

On the capex front, Solapur Phase 1 is progressing as planned and is expected to be operational in Q2 of this year.

Risks & concerns

  • Geopolitical conflicts and global demand uncertainties

    medium

    Ongoing geopolitical conflicts and uncertainties around global demand, supply chain disruptions, elevated logistics, and energy costs create a challenging environment.

    Management acknowledged

  • Raw material price volatility and supply chain constraints

    medium

    Solvents and other raw materials have seen price increases, and supply chains face constraints due to the war, though management expects to pass on costs.

    Management acknowledged

  • Price erosion in base business

    low

    The non-GPL, non-CDMO base business experienced approximately 5.5% price erosion, and overall portfolio saw about 4.5% erosion, though newer products are less commoditized.

    Management acknowledged

  • Volatility in GPL business

    low

    The GPL business is described as 'wavy,' and its contribution is expected to decrease as the non-GPL business grows faster, indicating potential fluctuations.

    Management acknowledged

Q&A highlights

7 direct
Impact of fire incident at Dahej plant Direct
So the fire at Dahej impacted only the intermediate side of the facility. The API, the finished area was intact. So we didn't experience any great delays. As a result of that, there is no significant spillover. There is some but not very significant. And we hope to be able to tide that by in Q1. ... From an expense perspective, yes, we have booked a loss due to fire in our other expenses to the extent of INR20 crores.

Clarified the operational and financial impact of a recent fire, quantifying the loss and confirming minimal production disruption.

Asked by Ahmed Madha

Forex gains and impact on gross margins Direct
So yes, there is an element of Forex gain for the year in the P&L. As you rightly mentioned that since we are net exporters, any rupee depreciation definitely helps us. For the entire year on the P&L, we have seen a net gain of about INR31 crores on the P&L. There is about INR11 crores of gain that we have booked for Q4 and about INR20 crores for the full year that we have booked.

Provided specific figures for Forex gains and confirmed their positive contribution to gross margins as a net exporter.

Asked by Ahmed Madha

Strategy for inorganic opportunities Direct
So we are actively looking and the direction is to basically enhance the platform that we already have. So our goal is to extract more value from our pretty large and diverse pipeline of APIs. So if we can sort of milk that pipeline much more through a lateral buildup of allied platforms, then that's the direction we are looking into in terms of inorganic.

Outlined the strategic rationale for potential inorganic growth, focusing on platform enhancement and value extraction from existing API pipeline rather than just market share.

Asked by Ahmed Madha

CDMO revenue flat vs. margin expansion Partial
So CDMO definitely has better margins, but our CDMO business has grown 18%. Why do we say it's flat? I don't know. ... So improvement in margin has got like, I would say, 3 to 4 factors. Operational efficiency has helped. We have had better cost processes implemented, CDMO has gone from 6% last year to 7% this year in terms of I mean, FY25, it was 6% it's gone to 7% in FY26 and that certainly matters. But we've also had some good launches of generic API in the multiple markets. So all in all, that is how we've achieved better margins.

Clarified that CDMO revenue was not flat but grew 18%, and explained the multiple factors (CDMO growth, operational efficiency, new launches) contributing to overall margin expansion.

Asked by Krishnendu Saha

Contribution of high potency API (HPAPI) to revenue Direct
So see, the only contribution that we get is from the sale of exhibit batch quantities because like I explained, the patent expiries are not going to happen until early 2028. So until then, our customers would not be able to launch and would not be able to buy API from us for those launches. So the only sort of revenue that comes from the high-potent segment right now is the sale of exhibit batch quantities.

Provided a clear timeline for significant HPAPI revenue contribution, indicating it's a long-term play tied to patent expiries (around 2028) rather than an immediate revenue driver.

Asked by Shubh Mehta

Price erosion in the base business (non-GPL, non-CDMO) Direct
Yes. So on that, the price erosion is about 5.5% is what we have seen on the non-GPL, non-CDMO.

Quantified the price erosion in a specific segment of the business, providing clarity on a potential headwind.

Asked by Shubh Mehta

Capacity utilization for new brownfield and greenfield facilities Direct
So we expect that in when Solapur starts off, we should start off with a robust 40% to 50% utilization and then probably take it up to 60%, 70% in the following year. ... And brownfield will kick in pretty quickly, 2 to 3 quarters.

Provided specific timelines and initial utilization targets for new capacity, differentiating between brownfield and greenfield projects.

Asked by Yog Rajani

Focus and future trajectory of R&D spend Direct
Alankar, the areas that you outlined are where we are focusing on R&D, and that's really going to drive the growth. As far as settling down, I don't think we'll cross 4%, right? We'll probably be at 4% in the next year or 2. And then it should settle down. ... I mean, you talked about flow chemistry, you talked about the CDMO side, and we are looking seriously into pellets and granules. That's also an area that we've started working on. It's that whole lateral expansion of the API. I mean, we call it API plus, right?

Clarified the strategic areas of R&D investment (flow chemistry, HPAPI, CDMO, pellets/granules, API plus) and provided a target for R&D spend as a percentage of sales (settling at 4% in 1-2 years).

Asked by Alankar Garude

3 min read 8 chapters

Detailed narrative

Strategic Shift and Non-GPL Business Growth

Alivus Life Sciences has successfully strengthened its business over the past two years, significantly reducing its dependence on the GPL business. The non-GPL segment's contribution to the overall business increased from 59% in FY22 to 71% in FY26, demonstrating a robust 13% year-on-year growth. This diversification, supported by strong demand in regulated markets and new product launches, is a key driver for the company's sustainable growth trajectory.

Record Profitability and Margin Expansion

The company achieved its highest-ever EBITDA margin of 33.6% in FY26, expanding by 360 basis points year-on-year. This significant improvement was attributed to a favorable product mix, disciplined cost management, and enhanced operational efficiencies, even without the benefit of PLI. Over the last two years (FY24-FY26), Alivus added INR270 crores in incremental revenue and INR220 crores in EBITDA, with EBITDA CAGR at 15.8%.

Aggressive Capacity Expansion and R&D Investment

Alivus is making substantial investments in capacity expansion and R&D for future growth. The company spent INR306 crores on capex in FY26 and plans to incur INR540 crores in FY27, entirely funded through internal accruals. These investments are directed towards building new capabilities at the greenfield Solapur project and strengthening the R&D platform. The goal is to expand API capacity from 1,198 KL in FY24 to a planned 2,690 KL by FY28.

Operational Efficiency and Cost Control

The company has focused on improving operational efficiency and implementing better cost processes. A notable initiative includes shifting from gas to briquette boilers, which helps stabilize operational costs and mitigate the impact of rising energy prices. This strategic move, combined with disciplined cost management, has been instrumental in driving the significant expansion of gross margins to 58.2% for FY26.

Robust Pipeline and High Potency API Development

Alivus maintains a strong pipeline with over 611 DMF and CEP filings globally. The high-potent API portfolio is a key focus, with 28 products in the pipeline, 12 of which are validated and 7 in advanced stages. While significant revenue from HPAPIs is anticipated post-2028 due to patent expiries, the company is actively investing in areas like flow chemistry and complex molecules to ensure long-term growth and differentiation.

Strong Cash Generation and Net Debt-Free Status

The company has demonstrated robust cash generation, accumulating INR984 crores from operations over the past two years. After allocating INR472 crores for capex and INR61 crores for dividends, Alivus maintains a 'war chest' of INR451 crores. As of March 31, 2026, cash and cash equivalents stood at INR782 crores, reinforcing its net debt-free position and providing financial flexibility for future growth initiatives.

CDMO Business Recovery and Future Outlook

The CDMO business experienced a meaningful recovery starting from Q3 FY26, driven by traction in existing projects and the scaling up of newer ones. Management expects this positive momentum to continue and aims to close two new CDMO deals in the early second half of FY27. This segment, with its inherently better margins, is a crucial component of the company's strategy to enhance overall profitability.

Diversified Geographical Presence

Alivus has a well-diversified geographical footprint, with significant contributions from mature markets such as India, Europe, Latin America, and the U.S. The company has also successfully expanded into newer geographies like Japan over the last 4-5 years, which is now growing well. This broad market presence, coupled with a strategy to select molecules suitable for various regions, ensures balanced growth across its portfolio.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls